State-of-the-Art Granulation Techniques in 2024

In the world of pharmaceutical manufacturing, granulation stands as a cornerstone process, pivotal to the production of oral solid dosage forms. In this dynamic sector, L.B. Bohle’s granulation systems represent the zenith of state-of-the-art technological advancement.

As the pharmaceutical industry continues to evolve in 2024, the role of granulation technology has become more critical than ever. Solid oral dosage forms constitute over 60% of pharmaceutical products, such as tablets, capsules, and coated tablets. Moreover, the demand for precise granulation in pharmaceutical processes is increasingly important as the industry moves towards more personalised medicine and seeks to improve the efficiency and quality of drug production. L.B. Bohle’s technology is instrumental in addressing these evolving demands, ensuring uniformity, improving product stability, and enabling the efficient production of complex drug formulations.

One of the World’s Largest Portfolios of Granulation Systems

L.B. Bohle’s granulation technology range stands at the forefront of the solid oral dosage manufacturing evolution, boasting one of the world’s largest and most comprehensive portfolios of cutting-edge granulation systems. The company’s granulation technology suite is a symphony of precision engineering and innovation, designed to meet the diverse needs of the pharmaceutical industry with remarkable efficiency and consistency.

At the heart of this suite is the Fluidized Bed System (BFS), a series that has become the benchmark for fluidized bed granulation. It uses the innovative Bohle Uni Cone BUC® process, which ensures complete fluidization of the particles and even film coating with no twin formation.

The High-Shear Granulation (GMA) system delivers consistent granule size and quality. Its precision-engineered agitator and chopper are the keystones of its operation, ensuring that the granulation process is both controlled and uniform.

The Compact Granulation System (BFS and GMA) combines the best of BFS and GMA technologies with a design that maximises space without compromising performance. This system is a testament to L.B. Bohle’s ingenuity, offering a versatile and efficient granulation process within an extremely reduced footprint.

The Single-Pot Granulation (VMA) system is a versatile unit that integrates mixing, granulation, and drying into a single operation. This streamlines the production process, reducing the complexity and enhancing the efficiency of pharmaceutical manufacturing.

The Twin-Screw Granulation (BCG) system represents the cutting edge of continuous wet granulation technology. It provides simultaneous material transport, kneading, and mixing, which are essential for achieving optimal granulation outcomes.

Joining this impressive lineup are the BRC dry granulator series and the QbCon 1, both of which have been honoured with the prestigious German Design Award 2024. This accolade is a testament to their innovative design and functionality, which stand out in the industry. The BRC dry granulators are renowned for their high production capacity and minimal material loss. Their precision in particle size control, makes them ideal for moisture-sensitive formulations. The granulators are suitable for continuous production and can be integrated with Process Analytical Technology (PAT), ensuring flexibility for integration into a broad variety of production frameworks. The system design emphasises hygienic operation, ergonomics, operator safety, and technical sophistication. The QbCon 1, a continuous granulator and dryer, is designed for research and development but scales seamlessly to full production, exemplifying the innovation that drives L.B. Bohle’s success.

The Benchmark for Excellence and Innovation

In 2024, L.B. Bohle’s granulation technology sets itself apart with a blend of innovation, efficiency, and user-centric design. These systems are not only technologically advanced but also designed for high throughput, meeting the increasing demand for medications without quality compromise.

The versatility of L.B. Bohle’s equipment provides effective solutions that span from lab-scale to full production. This adaptability is vital in an industry where precision and flexibility are key. Additionally, the systems are economical and resource-efficient, minimising waste and maximising yield, essential for cost-effective manufacturing. The user-friendly design emphasises ease of operation and quick cleaning, reducing downtime and boosting productivity. Ergonomic considerations also ensure operator comfort and safety, a growing priority in modern manufacturing.

The Impact of Modern Granulation Methods on Drug Formulations

The granulation technology by L.B. Bohle in 2024 has made a significant impact on drug formulation. The award-winning BRC dry granulators and the QbCon 1, are prime examples of such technology. The BRC dry granulators offer precise control over particle size and density to ensure uniformity in drug formulations, a critical factor for consistent drug delivery and efficacy. Meanwhile, the QbCon 1 facilitates a seamless transition from research to production, enabling the development of new drug formulations with improved bioavailability and stability.

Together, these technologies address the pharmaceutical industry’s need for rapid product development and the manufacturing of complex formulations, offering flexibility and efficiency.

Addressing Demands for Precise Granulation in Pharmaceutical Processes

In the precision-driven field of pharmaceutical manufacturing, L.B. Bohle’s granulation technology is critical, enhancing the flow, stability, and uniformity of oral solid dosage forms. This advancement not only improves the compressibility and dissolution profiles of tablets and capsules, leading to safer and more effective medications but also aligns with the shift towards personalised medicine.

As the demand for tailored drug treatments grows, L.B. Bohle’s systems prove indispensable, enabling the production of precise drug batches that cater to individual genetic profiles, thus embodying the convergence of innovation and patient-centric care in drug development.

L.B. Bohle’s Forward-thinking Granulation Portfolios

L.B. Bohle’s granulation technology represents a harmonious blend of cutting-edge features and designs, culminating in one of the world’s most extensive and forward-thinking portfolios. The system’s range not only satisfies the present demands of the pharmaceutical sector but also foresees and influences its trajectory. Their broad range of granulation methods sets a new benchmark for modern granulation, reflecting their status as a leading force in the industry. More than mere equipment, L.B. Bohle’s systems herald a new chapter in pharmaceutical manufacturing, emphasising ease of use, cost-effectiveness, and conservation of resources. As they continue to innovate, L.B. Bohle ensures their granulation technology remains a step ahead, reinforcing their role as a leading global manufacturer of state-of-the-art granulation systems.

Unlock the full potential of modern granulation methods with L.B. Bohle’s comprehensive White Paper, “Granulation Variety.” Click below to download: